Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of SHR-A1811 + chemotherapy + adebrelimab versus trastuzumab + chemotherapy + pembrolizumab in previously untreated unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
CTR20253128Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Sep 2025; status: active.
02
Drugs
trastuzumab rezetecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20253128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253128.